IL6 and breast cancer: In both BC-3 and BCBL-1 ascites-derived cells, ATO as a single agent had no significant effect on cellular IL-6, while Lena alone significantly decreased cellular IL-6 transcripts in both BC-3 (p < 0.01) and BCBL-1 cells (p < 0.05) to more than 50% as compared to untreated controls (Figure 3b).